Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics Inc (TRDA, Financial), executed a sale of 18,219 shares in the company on November 6, 2024. The transaction was filed through an SEC Filing. Following this transaction, the insider now owns 164,997 shares of Entrada Therapeutics Inc.
Entrada Therapeutics Inc is engaged in the development of various therapies targeting intracellular proteins. The company's innovative approach aims to address significant unmet medical needs.
Over the past year, the insider has sold a total of 42,279 shares and has not made any purchases. This recent sale is part of a broader trend observed at Entrada Therapeutics Inc, where there have been 20 insider sells and 6 insider buys over the past year.
On the date of the recent transaction, shares of Entrada Therapeutics Inc were trading at $18.62. This pricing sets the company's market cap at approximately $694.144 million. The price-earnings ratio of the stock stands at 6.29, which is lower than both the industry median of 26.79 and the historical median for the company.
The valuation metrics such as price-sales ratio, price-book ratio, and price-to-free cash flow are also critical in analyzing the stock's current standing and potential future performance.
For further insights into the stock's valuation, the GF Value can provide an estimation of its intrinsic value based on historical multiples, adjusted for future business growth expectations.
This insider sale could be a point of interest for current and potential investors, providing a snapshot of insider confidence and activity within Entrada Therapeutics Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
